Empagliflozin vs Zibotentan + Dapagliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline

Empagliflozin · Jardiance

Marketed by Boehringer Ingelheim and partners

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT03594110 · Phase 3 · completed

Patients with chronic kidney disease (6,609) were randomly assigned to empagliflozin 10 mg or matching placebo under double-blind conditions. The primary outcome was a composite of kidney disease progression or cardiovascular death. It was registered for the active trial and again for the whole study, which added up to 2 years of follow-up after the study drug stopped. Empagliflozin reduced the outcome in the active trial (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001) and over the whole study (hazard ratio 0.79, 95% CI 0.72 to 0.87). The figures come from the two published papers (N Engl J Med 2023 and 2025).

Next expected readout: December 2026 · NCT05786443 (registry estimate)

Reported efficacy

Time to first kidney disease progression or cardiovascular death (adjudicated): in the interventional part (up to 1136 days) and over the overall study including post-trial follow-up (up to 1869 days): Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met. (met)

Result source: NCT03594110

Zibotentan + Dapagliflozin

Developed by AstraZeneca

Phase 3 in Chronic Kidney Diseasesmall molecule (combination)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT06087835 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEmpagliflozinZibotentan + Dapagliflozin
Kidney composite outcome6.1% vs 8.1%−2 vs placebo10 mg · n 3304NCT03594110
1 other result
  • 7.5% vs 8.9% 10 mg · n 3304 · Phase 3 · secondary NCT03594110
—Trial running · NCT06087835
UACR, % change-39.1% vs -2.6%−36.5 vs placebo10 mg · wk 14 · n 61NCT05182840
5 other results
  • -36.6% vs -2.6% 20 mg · wk 14 · n 59 · Phase 2 · primary NCT05182840
  • -22.4% vs -2.6% 3 mg · wk 14 · n 65 · Phase 2 · primary NCT05182840
  • -19% vs -10.6% 10 mg + 3 mg · wk 14 · n 63 · Phase 2 · primary NCT05182840
  • -45.9% vs -10.6% 10 mg + 10 mg · wk 14 · n 60 · Phase 2 · primary NCT05182840
  • -40.3% vs -10.6% 10 mg + 20 mg · wk 14 · n 62 · Phase 2 · primary NCT05182840
—Trial running · NCT06087835
eGFR slope—Not posted · NCT05373680—Trial running · NCT06087835
Haemoglobin, change—Not posted · NCT05373680—Trial running · NCT06087835

Kidney composite outcome

Empagliflozin
6.1% vs 8.1%−2 vs placebo10 mg · n 3304NCT03594110
1 other result
  • 7.5% vs 8.9% 10 mg · n 3304 · Phase 3 · secondary NCT03594110
Zibotentan + Dapagliflozin
—Trial running · NCT06087835

UACR, % change

Empagliflozin
-39.1% vs -2.6%−36.5 vs placebo10 mg · wk 14 · n 61NCT05182840
5 other results
  • -36.6% vs -2.6% 20 mg · wk 14 · n 59 · Phase 2 · primary NCT05182840
  • -22.4% vs -2.6% 3 mg · wk 14 · n 65 · Phase 2 · primary NCT05182840
  • -19% vs -10.6% 10 mg + 3 mg · wk 14 · n 63 · Phase 2 · primary NCT05182840
  • -45.9% vs -10.6% 10 mg + 10 mg · wk 14 · n 60 · Phase 2 · primary NCT05182840
  • -40.3% vs -10.6% 10 mg + 20 mg · wk 14 · n 62 · Phase 2 · primary NCT05182840
Zibotentan + Dapagliflozin
—Trial running · NCT06087835

eGFR slope

Empagliflozin
—Not posted · NCT05373680
Zibotentan + Dapagliflozin
—Trial running · NCT06087835

Haemoglobin, change

Empagliflozin
—Not posted · NCT05373680
Zibotentan + Dapagliflozin
—Trial running · NCT06087835
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Zibotentan + Dapagliflozin: registry results are on file for Chronic Kidney Disease, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Empagliflozin: 4 of 4 rows · Zibotentan + Dapagliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEmpagliflozin
Dropout rate
22.9%10 mga
NCT03594110 · Phase 3
show 9 more results
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
12.1%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
7.2%10 mga
NCT03594110 · Phase 3
show 9 more results
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
4.8%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
Serious AEs
33%10 mga
NCT03594110 · Phase 3
show 9 more results
6.4%Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
7.1%Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
5.6%10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
8.3%20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
9.6%10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
6.8%10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
5.3%10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
4.3%3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
10 mga
gout 6.9% (placebo 7.9%)
NCT03594110 · Phase 3
show 8 more results
nasopharyngitis 4.1%
glomerular filtration rate decreased 3.8%
hyperkalaemia 3.8%
NCT05254002 · Phase 2 · registry result, not featured evidence
hyperkalaemia 9.3%
glomerular filtration rate decreased 6.3%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
10 mg
glomerular filtration rate decreased 9.9% (placebo 4.1%)
hyperkalaemia 9.9% (placebo 5.5%)
cortisol decreased 5.6% (placebo 0%)
NCT05182840 · Phase 2 · registry result, not featured evidence
20 mg
hyperkalaemia 23.6% (placebo 5.5%)
glomerular filtration rate decreased 8.3% (placebo 4.1%)
upper respiratory tract infection 4.2% (placebo 2.7%)
NCT05182840 · Phase 2 · registry result, not featured evidence
10 mg + 10 mg
hyperkalaemia 15.1% (placebo 5.5%)
glomerular filtration rate decreased 11% (placebo 4.1%)
hypotension 5.5% (placebo 0%)
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
10 mg + 20 mg
glomerular filtration rate decreased 9.5% (placebo 4.1%)
hyperkalaemia 9.5% (placebo 5.5%)
upper respiratory tract infection 5.4% (placebo 2.7%)
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
10 mg + 3 mg
hyperkalaemia 6.6% (placebo 5.5%)
glomerular filtration rate decreased 5.3% (placebo 4.1%)
cortisol decreased 2.6% (placebo 0%)
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
3 mg
hyperkalaemia 11.4% (placebo 5.5%)
cortisol decreased 4.3% (placebo 0%)
upper respiratory tract infection 2.9% (placebo 2.7%)
NCT05182840 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Empagliflozin

Time to Cardio-renal Composite Endpoint 6.85% (n=3304) vs 8.96% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
show 1 more result
8.36% (n=3304) vs 9.99% (n=3305) placebo10 mg
NCT03594110 · Phase 3
Time to Cardiovascular Composite Endpoint 2.04% (n=3304) vs 2.39% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Overall Survival 0.1% vs 0.1% placebo10 mg
time to event · count
NCT03594110 · Phase 3
Time to Composite Renal Endpoint 6.09% (n=3304) vs 8.09% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
show 1 more result
7.52% (n=3304) vs 8.95% (n=3305) placebo10 mg
NCT03594110 · Phase 3
Time to CV Death 0.91% (n=3304) vs 1.08% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to CV Death or ESKD 2.55% (n=3304) vs 3.45% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to Death or ESKD 5.13% (n=3304) vs 6.08% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to ESKD 2.72% (n=3304) vs 3.49% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
UACR 0.483 vs 0.708 Empagliflozin ratio @ 25.7wk
ratio to baseline · ratio
NCT05254002 · Phase 2 · registry result, not featured evidence
show 2 more results
0.483 vs 0.683 Finerenone ratio @ 25.7wk
NCT05254002 · Phase 2 · registry result, not featured evidence
0.818 vs 0.853 Finerenone ratio @ 30wk
NCT05254002 · Phase 2 · registry result, not featured evidence
eGFR 30% Decline 6.3% (n=268) vs 3.8% (n=264) Finerenone @ 4.3wk
event count · % of participants
NCT05254002 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted
UACR -0.496 vs -0.027 placebo mg @ 14wk10 mg
absolute change · mg
NCT05182840 · Phase 2 · registry result, not featured evidence
show 5 more results
-0.455 vs -0.027 placebo mg @ 14wk20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
-0.21 vs -0.112 Empagliflozin mg @ 14wk10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-0.614 vs -0.112 Empagliflozin mg @ 14wk10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-0.516 vs -0.112 Empagliflozin mg @ 14wk10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-0.254 vs -0.027 placebo mg @ 14wk3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
UACR -39.1% (n=61) vs -2.6% (n=69) placebo @ 14wk10 mg
percent change · % of baseline
NCT05182840 · Phase 2 · registry result, not featured evidence
show 5 more results
-36.6% (n=59) vs -2.6% (n=69) placebo @ 14wk20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
-19% (n=63) vs -10.6% (n=64) Empagliflozin @ 14wk10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-45.9% (n=60) vs -10.6% (n=64) Empagliflozin @ 14wk10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-40.3% (n=62) vs -10.6% (n=64) Empagliflozin @ 14wk10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-22.4% (n=65) vs -2.6% (n=69) placebo @ 14wk3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Empagliflozin's landscape · Zibotentan + Dapagliflozin's landscape